Loading ...

When the first messenger RNA (mRNA) vaccines proved effective during COVID, many experts viewed them as a short-term fix. Five years later, the same technology evolved into one of medicine’s most ambitious platforms, with applications now spanning cancer, rare diseases, and chronic conditions that were once considered out of reach.

Currently, mRNA extends well beyond the prevention of infectious diseases. Recent clinical trials have demonstrated potential in oncology, rare diseases, and personalized medicine, establishing it as one of the most active areas of biomedical innovation. Important challenges remain, including improving stability, targeting specific tissues, and extending the duration of therapeutic effects.

The widespread use of mRNA vaccines during the pandemic provided the technology’s first large-scale clinical validation. Unlike conventional drugs, mRNA does not act directly on a biological target or integrate into the genome. Instead, it provides temporary instructions that enable the cells to produce therapeutic proteins.

Programming Cells

This process is relatively simple. Researchers first designed an RNA sequence that encodes a specific protein. The sequence is then delivered into the body using lipid nanoparticles. Once inside cells, mRNA is translated into proteins that trigger a biological or immune response.

The development of lipid nanoparticles has been crucial for the success of mRNA technology. These particles protect RNA from degradation and facilitate cellular uptake, overcoming long-standing challenges related to instability and rapid breakdown. Their use has also shortened development timelines to approximately 4 weeks, an advantage that may prove critical during public health emergencies.

Cancer Vaccines

Cancer is a field in which mRNA technology has had the greatest impact. More than 100 clinical trials have evaluated mRNA-based approaches for lungs, breast, prostate, pancreatic, brain, and melanoma cancers.

A review published in MED (2025) highlighted the development of cancer vaccines that encode tumor-specific antigens and stimulate immune responses against malignant cells. A key advantage of this approach is its potential for personalization, allowing vaccines to be tailored to the molecular characteristics of an individual patient’s tumor.

For example, in melanoma, combining mRNA vaccines with immunotherapy reduced the risk for recurrence by up to 44%. In addition, data presented at the annual meeting of the European Society for Medical Oncology and published in Nature in 2025 suggested that 3 year survival rates were approximately twice as high among patients with melanoma who received an mRNA vaccine in combination with immunotherapy than among those who received immunotherapy alone.

Despite these advances, important challenges remain, including optimization of delivery and regulation of immune responses. Researchers are exploring the integration of AI and CRISPR-based approaches while continuing to refine mRNA design. More than 60 oncology therapies currently in development are expected to enter clinical testing by 2029.

Rare Diseases

In rare diseases, mRNA offers the possibility of replacing defective proteins without altering a person’s DNA, potentially avoiding the risks associated with permanent genetic modification. Development has progressed most rapidly in inherited metabolic liver disorders, in which the biodistribution of lipid nanoparticles is particularly favorable. This biological advantage helps explain why clinical translation has advanced more quickly in the liver than in other organs.

One notable example involves propionic acidemia and methylmalonic acidemia, where the candidate therapy, mRNA-3927, is being evaluated as a protein replacement treatment. Preliminary data from small cohorts of 12-16 patients suggested safety and possible clinical benefit, although the evidence remains inconclusive.

In a mouse model of argininosuccinic aciduria, a rare inherited metabolic disorder, lipid nanoparticle encapsulated mRNA, improved glutathione metabolism, restored key liver functions, and increased survival. Although these findings cannot be directly translated to humans, they provide proof of concept for mRNA-based treatment of rare genetic diseases.

In Spain, researchers involved in the NanoARPAH project are evaluating whether mRNA can be used to express the missing enzyme in mucopolysaccharidosis type I (Hurler syndrome) and reduce glycosaminoglycan accumulation.

Applications for Infectious Diseases and Chronic Diseases

In infectious diseases, mRNA technology has moved beyond COVID and into broader vaccine development. The most advanced programs focus on influenza, with tetravalent mRNA vaccines already in clinical trials. For respiratory syncytial virus, Moderna’s mRESVIA became the first approved mRNA vaccine for adults aged 60 years or older in 2025, being an important regulatory milestone for this technology.

Pfizer has also developed an mRNA influenza vaccine that is being evaluated in a phase 3 trial. The study enrolled more than 18,000 adults aged 18-64 years, with participants assigned to receive either the mRNA vaccine or a conventional influenza vaccine. Results published in The New England Journal of Medicine showed that the mRNA vaccine provided greater protection against influenza but was associated with a higher rate of adverse effects.

Researchers have also evaluated mRNA vaccines and therapies targeting chikungunya, Nipah virus, herpes simplex virus, rabies, yellow fever, and varicella zoster virus. These efforts highlight the flexibility of the platform and its ability to adapt to pathogens with diverse biological characteristics.

One of the principal scientific advantages of mRNA technology is its rapid adaptability, particularly for respiratory viruses with high antigenic variability, such as influenza. Compared with traditional vaccine platforms, mRNA enables faster updates and could prove valuable in settings that require dynamic epidemiologic surveillance. The challenge remains to balance immunogenicity and reactogenicity.

Applications for chronic diseases are still at a much earlier stage of development. Nevertheless, early research suggests potential utility across a range of complex conditions. In cardiovascular medicine, researchers are exploring whether mRNA can help regenerate heart tissue after myocardial infarction, potentially improving functional recovery. Researchers are studying whether the expression of specific proteins can interfere with beta amyloid accumulation in neurodegenerative diseases, such as Alzheimer’s disease.

In chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease, inhaled mRNA therapies could enable localized production of therapeutic proteins within the lungs while minimizing systemic exposure. Researchers are also investigating applications in autoimmune diseases, including rheumatoid arthritis and lupus, through the induction of immunomodulatory proteins, and in hemophilia through the restoration of clotting factor production.

Within just a few years, mRNA has evolved from a technology that gained widespread attention during the COVID pandemic into a platform with the potential to reshape modern medicine. Advances in nucleoside modification and lipid nanoparticle delivery have expanded their applications beyond vaccines to therapies for cancer, rare diseases, and chronic conditions. Significant challenges remain, including cost, logistics, and scalability; however, continued progress could transform the future of therapeutic development.

This article was translated from El Médico Interactivo on Univadis, part of the Medscape Professional Network.